This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Re…

Non-Hodgkin Lymphoma, AdultNon-Hodgkin Lymphoma, RefractoryNon-Hodgkin Lymphoma, Relapsed+4 more

~Estimated

~$10 – $8,750

Marker Therapeutics, Inc.NCT05798897

Cardiopulmonary Function and Cerebral Blood Flow in Hodgkin Lymphoma Survivors

SURVIVORS Study participants are being asked to take part in this research study called HODNIRS because the participant is a survivor of Hodgkin Lymphoma (HL)…

Hodgkin Lymphoma, Adult

~Estimated

~$10 – $750

St. Jude Children's Research HospitalNCT06421987

Phase 2

Pembrolizumab and GVD With ctDNA-guided Consolidation in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma: A Multicenter Phase 2 Study of the University of California Hematologic Malignancies Consortium

This is a single arm, open-label, multicenter, phase II study of pembrolizumab (pembro), gemcitabine, vinorelbine, and liposomal doxorubicin (GVD) in patients …

Hodgkin Lymphoma, AdultRefractory Hodgkin LymphomaClassic Hodgkin Lymphoma

~Estimated

~$10 – $7,500

Michael Spinner, MDNCT07021989